Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
Kester
Maartje I
MI
Verwey
Nicolaas A
NA
van Elk
Evert J
EJ
Scheltens
Philip
P
Blankenstein
Marinus A
MA
D000368:Aged; D000544:Alzheimer Disease / Q000097:blood* / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000032:analysis / Q000097:blood* / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000032:analysis / Q000097:blood / Q000134:cerebrospinal fluid; D001921:Brain / Q000378:metabolism / Q000503:physiopathology; D003072:Cognition Disorders / Q000097:blood* / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D003430:Cross-Sectional Studies; D018450:Disease Progression; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis / Q000097:blood* / Q000134:cerebrospinal fluid; D011237:Predictive Value of Tests; D012720:Severity of Illness Index
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42)